Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue skies and comfy breezes are greeting us. As for the official mascots, they have finished keeping passersby at bay and are now happily snoozing in their respective corners. As for us, we are firing up the trusty kettle for another cup of stimulation. Our choice today is peppermint, an old standby from our pantry. Of course, you are invited to join us. Meanwhile, here is the latest menu of tidbits. As always, do keep in touch. And best of luck today. …
Merck and Isomorphic Labs, the artificial intelligence drug designer built on a Nobel-winning technology that can model how molecules will bind to proteins, are entering into a research collaboration to discover small molecule candidates for an undisclosed oncology target of “strategic importance,” STAT reports. The partnership — only the latest such deal between a pharma giant and Isomorphic — will join Isomorphic’s proprietary drug design engine and existing wet lab data from Merck, which will handle the preclinical and clinical development, manufacturing, and commercializing of any products.
The U.S. Food and Drug Administration approved a Sanofi drug, making it the first treatment for a type of rare genetic condition that affects the brain and nervous system, Reuters writes. The drug, branded as Infilbray, was approved for adults and children weighing at least 15 kilograms, or about 33 pounds, with type 3 Gaucher disease, a rare inherited disorder that causes fatty substances to build up in the body and brain. The approval was based on a late-stage study of 43 patients aged 12 years and older whose symptoms outside the brain and nervous system had been stabilized with enzyme replacement therapy.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Source: www.statnews.com



